Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
14 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
Sperimentazioni cliniche nazionali
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (Everolimus) in patients with lymphangioleiomyomatosis (Phase II) - FR
Institution: Information not provided - FR
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis - FR
Institution: Information not provided - FR
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR
GERMANIA
Bayern
MÜNCHEN
EXIST-2: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (Phase III) - DE
LMU Klinikum der Universität München - Campus Innenstadt
Nephrologisches Zentrum
GERMANIA
Berlin
BERLIN
EXIST-2: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (Phase III) - DE
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik mit Schwerpunkt Nephrologie
ITALIA
LOMBARDIA
MILANO
Studio open label, non randomizzato di RAD001 (Everolimus) in pazienti affetti da Linfangioleiomiomatosi (Fase 2)
Ospedale San Giuseppe
U. O. di Pneumologia
REGNO UNITO; GRAN BRETAGNA
East Sussex
BRIGHTON
EXIST-2: A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (Phase III) - UK
Royal Sussex County Hospital
Sussex Kidney Unit
SPAGNA
Cataluña
BARCELONA
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III) (Completed)
Fundació Puigvert
Servicio de Nefrología
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease
Institution: Information not provided - DE
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital
Addenbrookes Hospital
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
BELGIO
VLAAMS BRABANT
LEUVEN
A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation
University Hospitals Leuven - Gasthuisberg
Pneumology department
BELGIO
VLAAMS BRABANT
LEUVEN
A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation
University Hospitals Leuven - Gasthuisberg
Pneumology department
Sperimentazioni cliniche internazionali
SVIZZERA
Suisse Alémanique
BASEL